Why is the gap between reported and adjusted EPS so large?

Adjusted results exclude special items such as amortization of acquired intangibles (a $0.84 per share impact for full-year 2024), restructuring and integration charges ($0.42), other charges, investment gains and losses, and excess tax benefits from stock compensation. Amortization is the largest driver and is expected to rise to about $160 million pre-tax in 2025 as acquisitions add intangible assets.

How much of Quest's revenue growth came from acquisitions rather than the core business?

Most of it. Management cited roughly 3% organic growth for full-year 2024 against 6.7% total growth, and about 5% organic growth in Q4 against nearly 15% total. Organic requisition volume grew only 0.6% in both Q4 and the full year, so investors should watch whether organic volume improves in 2025.

Is the 2025 guidance credible given the company's balance sheet and interest costs?

The guidance implies 8.4%–9.9% revenue growth and adjusted EPS growth of roughly 7%–10%, supported by the full-year contribution of 2024 acquisitions and health plan network expansions effective January 1, 2025. Higher debt and interest expense are a headwind, and the guidance does not appear to include additional large acquisitions, so results depend on integrating recent deals and on continued strong utilization.

Is the dividend safe after the increase?

The $3.20 annualized dividend cost roughly $355 million at current share count (about 111 million basic weighted shares), compared with 2024 operating cash flow of $1.33 billion and dividends paid of $331 million. Coverage from operating cash flow appears adequate, although the increase arrives while leverage has risen, so debt levels and free cash flow will determine room for future increases.

What do the 2025 cash flow guidance figures signal?

Management expects operating cash flow of about $1.45 billion, up roughly 9% from 2024, and capex of about $500 million, up roughly 18%. Together these imply free cash flow of roughly $950 million, a modest increase that would support debt reduction and dividend payments while continuing investment in automation, advanced diagnostics, and acquisitions.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 30, 2025. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported fourth quarter and full year 2024 results on January 30, 2025, posting strong top-line growth driven largely by acquisitions.

Q4 net revenues rose 14.5% to $2.62 billion^a, with requisition volume up 13.9% but organic requisition volume up only 0.6%, indicating growth was primarily acquisition-driven (including LifeLabs in Canada). Full-year revenues reached $9.87 billion, up 6.7%, with roughly 3% from organic growth. Reported diluted EPS for Q4 was $1.95 (up 14.7%), while adjusted diluted EPS was $2.23 (up 3.7%).

Full-year reported diluted EPS was $7.69^b (up 2.7%) and adjusted diluted EPS was $8.93 (up 2.5%). Adjusted operating margin for the full year held at 15.6%, down slightly from 15.8% in 2023, while reported operating margin was flat at 13.6%. For 2025, management guided to net revenues of $10.70 to $10.85 billion (8.4% to 9.9% growth), reported diluted EPS of $8.34 to $8.59, and adjusted diluted EPS of $9.55 to $9.80.

Cash from operations is expected to be about $1.45 billion^c and capex about $500 million. Balance sheet leverage increased meaningfully: long-term debt plus current portion rose to roughly $6.2 billion from $4.7 billion, largely to fund $2.16 billion in 2024 acquisitions, which increased goodwill and intangibles. Management also announced a 6.7% quarterly dividend increase to $0.80 per share, payable April 21, 2025 to holders of record on April 7, 2025, continuing a streak of annual increases since 2011.

For investors, the key takeaways are solid adjusted earnings growth and a constructive 2025 outlook, balanced against weak organic volume growth, rising interest expense (up to $201 million^d from $152 million), and a more leveraged balance sheet. Free cash flow in 2024 was about $909 million (operating cash flow of $1.33 billion less capex of $425 million), and the company repurchased $151 million of stock during the year.

02—Key points

Key Highlights

Q4 2024 net revenues of $2.62 billion, up 14.5% year over year, but organic requisition volume grew only 0.6%, so most growth was acquisition-driven.
Full-year 2024 net revenues of $9.87 billion, up 6.7%, with approximately 3% from organic growth; eight acquisitions were completed, including LifeLabs in Canada.
Q4 adjusted diluted EPS of $2.23 (up 3.7%) versus reported diluted EPS of $1.95 (up 14.7%); full-year adjusted diluted EPS of $8.93 (up 2.5%) versus reported $7.69 (up 2.7%).
2025 guidance calls for net revenues of $10.70–$10.85 billion (8.4%–9.9% growth) and adjusted diluted EPS of $9.55–$9.80, versus reported EPS of $8.34–$8.59.
Quarterly dividend raised 6.7% from $0.75 to $0.80 per share ($3.20 annualized), payable April 21, 2025, the company's annual increase since 2011.
Total debt rose to roughly $6.2 billion from $4.7 billion, and 2024 interest expense increased to $201 million from $152 million, reflecting acquisition financing.
Full-year 2024 operating cash flow of $1.33 billion and capex of $425 million, implying free cash flow of about $909 million; $151 million was spent on share repurchases.

03—Questions

Frequently Asked Questions

Why is the gap between reported and adjusted EPS so large?
Adjusted results exclude special items such as amortization of acquired intangibles (a $0.84 per share impact for full-year 2024), restructuring and integration charges ($0.42), other charges, investment gains and losses, and excess tax benefits from stock compensation. Amortization is the largest driver and is expected to rise to about $160 million pre-tax in 2025 as acquisitions add intangible assets.
How much of Quest's revenue growth came from acquisitions rather than the core business?
Most of it. Management cited roughly 3% organic growth for full-year 2024 against 6.7% total growth, and about 5% organic growth in Q4 against nearly 15% total. Organic requisition volume grew only 0.6% in both Q4 and the full year, so investors should watch whether organic volume improves in 2025.
Is the 2025 guidance credible given the company's balance sheet and interest costs?
The guidance implies 8.4%–9.9% revenue growth and adjusted EPS growth of roughly 7%–10%, supported by the full-year contribution of 2024 acquisitions and health plan network expansions effective January 1, 2025. Higher debt and interest expense are a headwind, and the guidance does not appear to include additional large acquisitions, so results depend on integrating recent deals and on continued strong utilization.
Is the dividend safe after the increase?
The $3.20 annualized dividend cost roughly $355 million at current share count (about 111 million basic weighted shares), compared with 2024 operating cash flow of $1.33 billion and dividends paid of $331 million. Coverage from operating cash flow appears adequate, although the increase arrives while leverage has risen, so debt levels and free cash flow will determine room for future increases.
What do the 2025 cash flow guidance figures signal?
Management expects operating cash flow of about $1.45 billion, up roughly 9% from 2024, and capex of about $500 million, up roughly 18%. Together these imply free cash flow of roughly $950 million, a modest increase that would support debt reduction and dividend payments while continuing investment in automation, advanced diagnostics, and acquisitions.

04—Continue

← View all 8-K filings